Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arrowhead Pharmaceuticals (ARWR) Gains from Investment Securities (2016 - 2025)

Arrowhead Pharmaceuticals (ARWR) has disclosed Gains from Investment Securities for 16 consecutive years, with $9.9 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 89963.64% year-over-year to $9.9 million, compared with a TTM value of $10.7 million through Dec 2025, up 1051.61%, and an annual FY2025 reading of $814000.0, up 1117.5% over the prior year.
  • Gains from Investment Securities was $9.9 million for Q4 2025 at Arrowhead Pharmaceuticals, up from $733000.0 in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $9.9 million in Q4 2025 and bottomed at -$3.1 million in Q3 2024.
  • Average Gains from Investment Securities over 5 years is $1.8 million, with a median of $1.1 million recorded in 2024.
  • Peak annual rise in Gains from Investment Securities hit 89963.64% in 2025, while the deepest fall reached 101.02% in 2025.
  • Year by year, Gains from Investment Securities stood at $3.2 million in 2021, then crashed by 100.06% to -$2000.0 in 2022, then plummeted by 49850.0% to -$999000.0 in 2023, then surged by 101.1% to $11000.0 in 2024, then surged by 89963.64% to $9.9 million in 2025.
  • Business Quant data shows Gains from Investment Securities for ARWR at $9.9 million in Q4 2025, $733000.0 in Q3 2025, and $81000.0 in Q2 2025.